October 2, 2014


May 18, 2016

Challenges: Crowdsourced solutions

A commentary in the most recent issue of the journal Nature discusses how DREAM Challenges and other open competitions bring new minds, skills and collaborations to problems in biomedical research. (Read More)

November 17, 2015

International team launches community competition to understand tumor origins and evolution

An international consortium of groups from Canada, the United States and the United Kingdom have come together to create an innovative, cloud-based, public challenge running on the Google Cloud Platform to optimize the discovery of genetically distinct groups of cells within cancers that could respond differently to treatment and have different risk of spreading. (Read more)

November 10, 2015

THINK: Applying Big Data Analytics to Answer More Questions About ALS

Each year, more than 5,600 Americans are diagnosed with Amyotrophic Lateral Sclerosis (ALS), also called Lou Gehrig’s Disease. This diagnosis usually prompts more questions from patients and family members about longevity and quality of life than what physicians can immediately answer. (Read more)

November 5, 2015

Prize4Life, Sage Bionetworks and DREAM Announce Winners of ALS Stratification Challenge

Today, Prize4Life, Sage Bionetworks and the DREAM community announced the winners of the DREAM ALS Stratification Prize4Life Challenge, a global data analysis competition to computationally identify different subgroups of ALS patients. In ALS, there is currently no way to determine whether someone living with the disease will survive the average of 3-5 years after diagnosis or live with ALS for decades. The goal of the Challenge is to find answers that may inform clinical practice, new trial designs, and ultimately personalized approaches to the discovery and development of new ALS medicines.  (Read more)

October 19, 2015

Winners Recognized for Crowdsourcing and Data Sharing Competition to Drive Innovation in Prostate Cancer Research

Winners of the Prostate Cancer DREAM Challenge were formally recognized at the Prostate Cancer Foundation’s 22nd Annual Scientific Retreat, October 8-10, in Washington, D.C. The Prostate Cancer DREAM Challenge is the first research challenge in prostate cancer to marry crowdsourcing with data sharing, paving a new way to tackle key research questions about metastatic castration-resistant prostate cancer (mCRPC), an advanced form of the disease with poor outcomes. (Read more)

October 13, 2015

Dreaming big: the new DREAM Challenges channel

We are very excited to announce our latest collaboration here at F1000Research, which is with the excellent team at Dream Challenges. DREAM, which stands for Dialogue for Reverse Engineering Assessment and Methods, has led the way in innovating crowd sourced collaborations between academia, industry and not for profits to answer important biomedical questions that have a significant impact human health. (Read more)

October 7, 2015

The White House Celebrates the Five-Year Anniversary of Challenge.gov with More Than 20 New Prizes

On October 7, 2015, the White House is celebrating the five-year anniversary of Challenge.gov, by announcing a new set of innovative challenges in various disciplines.  The DREAM Challenge Community is very excited to be a participant in these new challenges announced by the Administration today.  The “Digital Mammography DREAM Challenge” is one of the two Coding4Cancer challenges announced by the White House. Launching in early spring 2016, the Coding4Cancer “consortium”will make available up to $1.2 million in cash prizes. This challenge seeks to improve the accuracy of breast cancer detection and reduce the current rate of patient callbacks. (Read More)

September 22, 2015

AstraZeneca supports crowd sourcing challenge to find new combination therapies for cancer

AstraZeneca is making available preclinical data from over 50 of its medicines as part of the DREAM Challenge, an open innovation competition, to find the most synergistic drug combinations with the potential to treat cancer. Public release of a data set of this scale is unprecedented and is intended to help advance research into combination cancer therapy across the global scientific community. Its release underscores AstraZeneca’s commitment to open innovation and reinforces the company’s belief that therapeutic combinations have the potential to transform the way cancer is treated. (Read more)